{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:57:10Z","timestamp":1766401030536,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jfma.2021.05.026","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T01:51:16Z","timestamp":1623376276000},"page":"409-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P2","title":["Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease"],"prefix":"10.1016","volume":"121","author":[{"given":"Ping-Song","family":"Chou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzyh-Chyuan","family":"Hour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4894-7055","authenticated-orcid":false,"given":"Chen-Wen","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-9021","authenticated-orcid":false,"given":"Yuan-Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2021.05.026_bib1","first-page":"293","article-title":"The efficacy and safety of donepezil in patients with alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The donepezil study group","volume":"7","author":"Rogers","year":"1996","journal-title":"Dementia"},{"key":"10.1016\/j.jfma.2021.05.026_bib2","first-page":"303","article-title":"Donepezil in Alzheimer's disease: from conventional trials to pharmacogenetics","volume":"3","author":"Cacabelos","year":"2007","journal-title":"Neuropsychiatric Dis Treat"},{"key":"10.1016\/j.jfma.2021.05.026_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3233\/JAD-2010-100936","article-title":"Plasma concentration of donepezil to the therapeutic response of Alzheimer's disease in Taiwanese","volume":"23","author":"Yang","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jfma.2021.05.026_bib4","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2147\/CIA.S159920","article-title":"Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients","volume":"13","author":"Zhang","year":"2018","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jfma.2021.05.026_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17425255.2020.1779700","article-title":"Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease","volume":"16","author":"Cacabelos","year":"2020","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.jfma.2021.05.026_bib6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jfma.2021.05.026_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40263-016-0356-1","article-title":"Effect of the CYP2D6 and APOE polymorphisms on the efficacy of donepezil in patients with alzheimer's disease: a systematic Review and meta-analysis","volume":"30","author":"Xiao","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jfma.2021.05.026_bib8","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2021.05.026_bib9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2021.05.026_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jfma.2021.05.026_bib11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000066024","article-title":"Cutoff scores of the cognitive abilities screening instrument, Chinese version in screening of dementia","volume":"14","author":"Lin","year":"2002","journal-title":"Dement Geriatr Cognit Disord"},{"key":"10.1016\/j.jfma.2021.05.026_bib12","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/elps.200800276","article-title":"Sensitive analysis of donepezil in plasma by capillary electrophoresis combining on-column field-amplified sample stacking and its application in Alzheimer's disease","volume":"29","author":"Yeh","year":"2008","journal-title":"Electrophoresis"},{"key":"10.1016\/j.jfma.2021.05.026_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169233","article-title":"Analysis of genetic variation in CYP450 genes for clinical implementation","volume":"12","author":"Goh","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jfma.2021.05.026_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5395\/rde.2017.42.2.152","article-title":"Statistical notes for clinical researchers: chi-squared test and Fisher's exact test","volume":"42","author":"Kim","year":"2017","journal-title":"Restor Dent Endod"},{"key":"10.1016\/j.jfma.2021.05.026_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1212\/WNL.0b013e3181b6bbe3","article-title":"Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease","volume":"73","author":"Pilotto","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2021.05.026_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FPC.0b013e32833f984c","article-title":"Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease","volume":"21","author":"Seripa","year":"2011","journal-title":"Pharmacogenetics Genom"},{"key":"10.1016\/j.jfma.2021.05.026_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3233\/JAD-2012-112123","article-title":"Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients","volume":"30","author":"Albani","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jfma.2021.05.026_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2147\/NDT.S46689","article-title":"Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer's disease","volume":"9","author":"Klimkowicz-Mrowiec","year":"2013","journal-title":"Neuropsychiatric Dis Treat"},{"key":"10.1016\/j.jfma.2021.05.026_bib19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000367596","article-title":"Influence of the rs1080985 single nucleotide polymorphism of the CYP2D6 gene and APOE polymorphism on the response to donepezil treatment in patients with alzheimer's disease in China","volume":"4","author":"Liu","year":"2014","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2021.05.026_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1017\/S1041610297004870","article-title":"Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type","volume":"9","author":"Morris","year":"1997","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.jfma.2021.05.026_bib21","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1373\/49.6.1008","article-title":"CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism","volume":"49","author":"Gaedigk","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.jfma.2021.05.026_bib22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008571-200110000-00004","article-title":"Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6","volume":"11","author":"Zanger","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jfma.2021.05.026_bib23","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3389\/fphar.2020.00934","article-title":"Gene polymorphisms affecting the pharmacokinetics and pharmacodynamics of donepezil efficacy","volume":"11","author":"Lu","year":"2020","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2021.05.026_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-2125.1998.0460s1007.x","article-title":"Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses","volume":"46","author":"Rogers","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jfma.2021.05.026_bib25","doi-asserted-by":"crossref","first-page":"16808","DOI":"10.1038\/s41598-020-73911-6","article-title":"Disease progression modeling of Alzheimer's disease according to education level","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621002412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621002412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:46:25Z","timestamp":1760539585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664621002412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0929664621002412"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2021.05.026","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2021.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}